Professor Andrew Biankin

Regius Chair of Surgery/Director of Translational Research Centre (Clinical Research Garscube)

telephone: 0141 330 5670
email: Andrew.Biankin@glasgow.ac.uk

Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1QH

Import to contacts

https://orcid.org/0000-0002-0362-5597

Biography

Andrew V. Biankin
A.O., B.Med.Sc., M.B.,B.S.(HONS), F.R.A.C.S., F.F.S.(R.C.P.A.), F.R.C.S.(Glasg), F.R.C.S.(Edin), Ph.D., F.R.S.E., F.Med.Sci.

Regius Professor of Surgery
Director, Wolfson Wohl Cancer Research Centre, University of Glasgow
Chairman, Precision-Panc Therapeutic Development Platform
Executive Director, ICGC-ARGO (International Cancer Genome Consortium Accelerating Research in Genomic Oncology)
Director, GPOL (Glasgow Precision Oncology Laboratory)
Specialist Consultant in Precision Oncology and Therapeutic Development

Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology. He has leadership roles in national and international consortia in cancer genomics and therapeutic development. He has authored over 160 articles in major journals including seminal works on cancer, genomics and precision medicine.

His work is currently focused on implementing Precision Oncology Practice in Health Systems internationally.

Research interests

Andrew Biankin is a surgeon-scientist whose research goals are to improve outcomes for individuals with pancreatic cancer through the development of early detection and novel therapeutic strategies based on molecular phenotyping and the delineation and implementation of biomarkers that facilitate clinical decision-making. He contributes to the International Cancer Genome Consortium through extensively characterising the genomic, transcriptomic and epigenomic aberrations in pancreatic cancer, and is extending this knowledge to a personalized model of cancer care, where molecular characteristics guide treatment decisions.

Biography

Associates

Fraser Duthie: Honorary Clinical Senior Lecturer, Consultant Pathologist. fraser.duthie@glasgow.ac.uk

Janet Graham: Consultant Medical Oncologist and NRS Research Fellow BWOSCC. janet.graham@ggc.scot.nhs.uk

Nigel Jamieson: Senior Clinical Lecturer in General Surgery (Medicine). Nigel.jamieson@glasgow.ac.uk

Ke Yuan: Lecturer in Computing Science (Machine Learning in Computational Biology). Ke.Yuan@glasgow.ac.uk

Georgios Gemenetzis: Honorary Clinical Lecturer.
georgios.gememetzis@glasgow.ac.uk

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Number of items: 145.

2024

Casolino, R. et al. (2024) Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA: A Cancer Journal for Clinicians, (doi: 10.3322/caac.21825) (PMID:38174605) (Early Online Publication)

2023

Golan, T., Casolino, R., Biankin, A. V. , Hammel, P., Whitaker, K. D., Hall, M. J. and Riegert-Johnson, D. L. (2023) Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Therapeutic Advances in Medical Oncology, (doi: 10.1177/17588359231189127) (PMID:37720496) (PMCID:PMC10504836) (Early Online Publication)

Wood, C. S. et al. (2023) Spatially resolved transcriptomics deconvolutes prognostic histological subgroups in patients with colorectal cancer and synchronous liver metastases. Cancer Research, 83(8), pp. 1329-1344. (doi: 10.1158/0008-5472.CAN-22-2794) (PMID:37057593) (PMCID:PMC10102851)

Tempero, M. A. et al. (2023) Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. Journal of Clinical Oncology, 41(11), pp. 2007-2019. (doi: 10.1200/JCO.22.01134) (PMID:36521097) (PMCID:PMC10082313)

Paiella, S. et al. (2023) A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing. ESMO Open, 8(2), 100881. (doi: 10.1016/j.esmoop.2023.100881) (PMID:36822114) (PMCID:PMC10163165)

Canel, M. et al. (2023) FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. Gut, (doi: 10.1136/gutjnl-2022-327927) (PMID:36977556) (Early Online Publication)

Casolino, R. et al. (2023) Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncology, 24(2), pp. 123-125. (doi: 10.1016/S1470-2045(23)00007-4) (PMID:36725142)

Dreyer, S. B. et al. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277(2), e396-e405. (doi: 10.1097/SLA.0000000000005050) (PMID:36745763) (PMCID:PMC9831035)

2022

Ali, A. et al. (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. American Journal of Cancer Research, 12(12), pp. 5668-5683. (PMID:36628279) (PMCID:PMC9827095)

Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)

Moser, R. et al. (2022) Pharmacological targeting of TFIIH suppresses KRAS mutant pancreatic ductal adenocarcinoma and synergizes with TRAIL. Cancer Research, 82(18), pp. 3375-3393. (doi: 10.1158/0008-5472.CAN-21-4222) (PMID:35819261)

Beer, P. A. and Biankin, A. V. (2022) Bridging the implementation gap: delivering complex genomic analysis for routine cancer care. Annals of Oncology, 33(9), pp. 857-859. (doi: 10.1016/j.annonc.2022.06.015) (PMID:35931317)

Zeng, S. et al. (2022) CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 41, 241. (doi: 10.1186/s13046-022-02443-w) (PMID:35945614) (PMCID:PMC9364549)

Horgan, D. et al. (2022) Meeting the need for a discussion of unmet medical need. Healthcare, 10(8), 1578. (doi: 10.3390/healthcare10081578) (PMID:36011235) (PMCID:PMC9408346)

Casolino, R., Corbo, V., Beer, P., Hwang, C.-I., Paiella, S., Silvestri, V., Ottini, L. and Biankin, A. V. (2022) Germline aberrations in pancreatic cancer: implications for clinical care. Cancers, 14(13), 3239. (doi: 10.3390/cancers14133239) (PMID:35805011) (PMCID:PMC9265115)

Patel, M. et al. (2022) Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 126(12), pp. 1704-1714. (doi: 10.1038/s41416-022-01729-2) (PMID:35173303) (PMCID:PMC9174220)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

2021

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)

Murphy, K. J. et al. (2021) Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Science Advances, 7(40), eabh0363. (doi: 10.1126/sciadv.abh0363) (PMID:34586840) (PMCID:PMC8480933)

Casolino, R. et al. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39(23), pp. 2617-2631. (doi: 10.1200/JCO.20.03238) (PMID:34197182) (PMCID:PMC8331063)

Schwappacher, R. et al. (2021) Muscle-derived cytokines reduce growth, viability and migratory activity of pancreatic cancer cells. Cancers, 13(15), 3820. (doi: 10.3390/cancers13153820)

Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, 155. (doi: 10.1038/s42003-020-01469-0) (PMID:33536587) (PMCID:PMC7859232)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Griffith, B. G.C., Upstill-Goddard, R., Brunton, H., Grimes, G. R., Biankin, A. , Serrels, B., Byron, A. and Frame, M. C. (2021) FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs. Scientific Reports, 11, 229. (doi: 10.1038/s41598-020-80111-9) (PMID:33420223) (PMCID:PMC7794255)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

Froeling, F. E.M. , Casolino, R., Pea, A., Biankin, A. V. and Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10(1), 149. (doi: 10.3390/jcm10010149) (PMID:33406790) (PMCID:PMC7794969)

2020

Beer, P. A., Cooke, S. L. , Chang, D. K. and Biankin, A. V. (2020) Defining the clinical genomic landscape for real-world precision oncology. Genomics, 112(6), pp. 5324-5330. (doi: 10.1016/j.ygeno.2020.10.032) (PMID:33144218) (PMCID:PMC7758710)

Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, 4748. (doi: 10.1038/s41467-020-18151-y) (PMID:32958763) (PMCID:PMC7505971)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)

Muthalagu, N. et al. (2020) Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discovery, 10(6), pp. 872-887. (doi: 10.1158/2159-8290.CD-19-0620) (PMID:32200350) (PMCID:PMC7611248)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, et al. (2020) Pan-cancer analysis of whole genomes. Nature, 578(7793), pp. 82-93. (doi: 10.1038/s41586-020-1969-6) (PMID:32025007) (PMCID:PMC7025898)

Jiao, W. et al. (2020) A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature Communications, 11, 728. (doi: 10.1038/s41467-019-13825-8) (PMID:32024849) (PMCID:PMC7002586)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32(1), pp. 1-4. (doi: 10.1016/j.clon.2019.07.011) (PMID:31378449)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32(1), pp. 5-8. (doi: 10.1016/j.clon.2019.08.007) (PMID:31522943)

2019

Beer, P. A., Cooke, S. L. , Chang, D. K. and Biankin, A. V. (2019) Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. Annals of Oncology, 30(11), pp. 1691-1694. (doi: 10.1093/annonc/mdz392) (PMID:31665210)

Tandon, M. et al. (2019) Prolactin promotes fibrosis and pancreatic cancer progression. Cancer Research, 79(20), pp. 5316-5327. (doi: 10.1158/0008-5472.CAN-18-3064) (PMID:31395607) (PMCID:PMC6801092)

Jackstadt, R. et al. (2019) Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell, 36(3), 319-336.e7. (doi: 10.1016/j.ccell.2019.08.003) (PMID:31526760) (PMCID:PMC6853173)

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi: 10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 249(3), pp. 332-342. (doi: 10.1002/path.5320) (PMID:31259422) (PMCID:PMC6852434)

Halbrook, C. J. et al. (2019) Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabolism, 29(6), 1390-1399.e6. (doi: 10.1016/j.cmet.2019.02.001) (PMID:30827862) (PMCID:PMC6602533)

Collisson, E. A., Bailey, P. , Chang, D. K. and Biankin, A. V. (2019) Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 16, pp. 207-220. (doi: 10.1038/s41575-019-0109-y) (PMID:30718832)

Dreyer, S. B. et al. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8(2), 16. (doi: 10.21037/cco.2019.04.06) (PMID:31070037)

2018

Chou, A. et al. (2018) Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67(12), pp. 2142-2155. (doi: 10.1136/gutjnl-2017-315144) (PMID:29080858) (PMCID:PMC6241608)

Pinho, A. V. et al. (2018) ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling. Nature Communications, 9, 5083. (doi: 10.1038/s41467-018-07497-z) (PMID:30504844) (PMCID:PMC6269509)

Veenstra, V.L. et al. (2018) ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 7, 87. (doi: 10.1038/s41389-018-0096-9) (PMID:30442938) (PMCID:PMC6237826)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23(5), pp. 1448-1460. (doi: 10.1016/j.celrep.2018.03.131) (PMID:29719257) (PMCID:PMC5946718)

Sheahan, A. V., Biankin, A. V. , Parish, C. R. and Khachigian, L. M. (2018) Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget, 9(30), pp. 21613-21627. (doi: 10.18632/oncotarget.25085) (PMID:29765563) (PMCID:PMC5940404)

Chin, V., Nagrial, A., Sjoquist, K., O'Connor, C. A., Chantrill, L., Biankin, A. V. , Scholten, R. J.P.M. and Yip, D. (2018) Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews, 2018(3), CD011044. (doi: 10.1002/14651858.cd011044.pub2) (PMID:29557103) (PMCID:PMC6494171)

Grant, R. C. et al. (2018) Exome-wide association study of pancreatic cancer risk. Gastroenterology, 154(3), 719-722.e3. (doi: 10.1053/j.gastro.2017.10.015) (PMID:29074453) (PMCID:PMC5811358)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Shroff, R. T. et al. (2018) Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precision Oncology, 2(1), (doi: 10.1200/po.17.00316) (PMID:30051098) (PMCID:PMC6057747)

2017

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi: 10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi: 10.1038/nature24462) (PMID:29132146) (PMCID:PMC6145146)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi: 10.1038/nature24026) (PMID:28953865)

Raphael, B. J. et al. (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell, 32(2), 185-203.e13. (doi: 10.1016/j.ccell.2017.07.007) (PMID:28810144) (PMCID:PMC5964983)

Harris, N.L.E. et al. (2017) SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene, 36(30), pp. 4288-4298. (doi: 10.1038/onc.2017.63) (PMID:28346421) (PMCID:PMC5537606)

Feigin, M. E. et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 49(6), pp. 825-833. (doi: 10.1038/ng.3861) (PMID:28481342) (PMCID:PMC5659388)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi: 10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Jung, L.A. et al. (2017) OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. Oncogene, 36(14), pp. 1911-1924. (doi: 10.1038/onc.2016.354) (PMID:27748763)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9(384), eaai8504. (doi: 10.1126/scitranslmed.aai8504) (PMID:28381539) (PMCID:PMC5777504)

Dreyer, S. B., Chang, D. K. , Bailey, P. and Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23(7), pp. 1638-1646. (doi: 10.1158/1078-0432.CCR-16-2411) (PMID:28373362)

Pishvaian, M. J., Biankin, A. V. , Bailey, P. , Chang, D. K. , Laheru, D., Wolfgang, C. L. and Brody, J. R. (2017) BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 116, pp. 1021-1026. (doi: 10.1038/bjc.2017.40) (PMID:28291774)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi: 10.1038/nature21063) (PMID:28199314)

Biankin, A. V. (2017) The road to precision oncology. Nature Genetics, 49(3), pp. 320-321. (doi: 10.1038/ng.3796) (PMID:28232728)

Vallejo, A. et al. (2017) An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 8, 14294. (doi: 10.1038/ncomms14294) (PMID:28220783) (PMCID:PMC5321758)

Hardie, R.-A. et al. (2017) Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer and Metabolism, 5, 2. (doi: 10.1186/s40170-017-0164-1) (PMID:28163917) (PMCID:PMC5282905)

Byrne, A. T. et al. (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 17, pp. 254-268. (doi: 10.1038/nrc.2016.140) (PMID:28104906)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)

Martinelli, P. et al. (2017) GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 66, pp. 1665-1676. (doi: 10.1136/gutjnl-2015-311256) (PMID:27325420) (PMCID:PMC5070637)

2016

Sharbeen, G., Youkhana, J., Mawson, A., McCarroll, J., Nunez, A., Biankin, A. , Johns, A., Goldstein, D. and Phillips, P. (2016) MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget, 8(6), pp. 9216-9229. (doi: 10.18632/oncotarget.13985) (PMID:27999205)

Roy, N. et al. (2016) PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Genes and Development, 30(24), pp. 2669-2683. (doi: 10.1101/gad.291021.116) (PMID:28087712)

Sharbeen, G., McCarroll, J., Liu, J., Youkhana, J., Limbri, L.F., Biankin, A.V. , Johns, A., Kavallaris, M., Goldstein, D. and Phillips, P.A. (2016) Delineating the role of βIV-Tubulins in pancreatic cancer: βIVb-tubulin inhibition sensitizes pancreatic cancer cells to vinca alkaloids. Neoplasia, 18(12), pp. 753-764. (doi: 10.1016/j.neo.2016.10.011) (PMID:27889644) (PMCID:PMC5126129)

Bailey, P. et al. (2016) Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 6, 35848. (doi: 10.1038/srep35848) (PMID:27762323) (PMCID:PMC5071896)

Humphrey, E. S. et al. (2016) Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Molecular and Cellular Proteomics, 15(8), pp. 2671-2685. (doi: 10.1074/mcp.M116.058313) (PMID:27259358) (PMCID:PMC4974343)

Swanton, C. et al. (2016) Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 27(8), pp. 1443-1448. (doi: 10.1093/annonc/mdw192) (PMID:27143638)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Kleeff, J. et al. (2016) Pancreatic cancer. Nature Reviews Disease Primers, 2, 16022. (doi: 10.1038/nrdp.2016.22) (PMID:27158978)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)

Humphris, J. L. and Biankin, A. V. (2016) Diagnosis and management of hereditary pancreatic cancer. In: Pichert, G. and Jacobs, C. (eds.) Rare Hereditary Cancers: Diagnosis and Management. Series: Recent results in cancer research (205). Springer International Publishing: Cham, pp. 61-83. ISBN 9783319299969 (doi: 10.1007/978-3-319-29998-3_5)

2015

Basturk, O. et al. (2015) A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas. American Journal of Surgical Pathology, 39(12), pp. 1730-1741. (doi: 10.1097/PAS.0000000000000533) (PMID:26559377) (PMCID:PMC4646710)

Nagrial, A. M., Chin, V. T., Sjoquist, K. M., Pajic, M., Horvath, L. G., Biankin, A. and Yip, D. (2015) Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 96(3), pp. 483-497. (doi: 10.1016/j.critrevonc.2015.07.007) (PMID:26481952)

Jamieson, N. B. , Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi: 10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi: 10.1111/cge.12536) (PMID:25388820)

Chantrill, L.A. et al. (2015) Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clinical Cancer Research, 21(9), pp. 2029-2037. (doi: 10.1158/1078-0432.CCR-15-0426) (PMID:25896973)

Susanto, J. M. et al. (2015) The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. International Journal of Oncology, 46(5), pp. 2223-30. (doi: 10.3892/ijo.2015.2894) (PMID:25695794)

Carlino, M.S. et al. (2015) New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Journal of Clinical Oncology, 33(11), e52-e56. (doi: 10.1200/JCO.2013.51.5783) (PMID:24821886)

Humphris, J., Chang, D. K. and Biankin, A. V. (2015) Inherited susceptibility to pancreatic cancer in the era of next-generation sequencing. Gastroenterology, 148(3), pp. 496-498. (doi: 10.1053/j.gastro.2015.01.009) (PMID:25613311)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

McCarroll, J. A. et al. (2015) βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget, 6(4), pp. 2235-2249. (PMID:25544769) (PMCID:PMC4385848)

Biankin, A. V. , Piantadosi, S. and Hollingsworth, S. J. (2015) Patient-centric trials for therapeutic development in precision oncology. Nature, 526, pp. 361-370. (doi: 10.1038/nature15819) (PMID:26469047)

Chin, V., Nagrial, A., Chou, A., Biankin, A. V. , Gill, A., Timpson, P. and Pajic, M. (2015) Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 17, e17. (doi: 10.1017/erm.2015.17) (PMID:26507949)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi: 10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Tactacan, C.M., Phua, Y.W., Liu, L., Zhang, L., Humphrey, E.S., Cowley, M., Pinese, M., Biankin, A.V. and Daly, R.J. (2015) The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Molecular Cancer, 14, 139. (doi: 10.1186/s12943-015-0412-3) (PMID:26215634) (PMCID:PMC4517651)

2014

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi: 10.1002/cncr.28863) (PMID:25313458)

Hudson, A. M., Yates, T., Li, Y., Trotter, E. W., Fawdar, S., Chapman, P., Lorigan, P., Biankin, A. , Miller, C. and Brognard, J. (2014) Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Research, 74(22), pp. 6390-6396. (doi: 10.1158/0008-5472.CAN-14-1020) (PMID:25256751)

Grimont, A. et al. (2014) SOX9 regulates ERBB signalling in pancreatic cancer development. Gut, 64(11), pp. 1790-1799. (doi: 10.1136/gutjnl-2014-307075) (PMID:25336113)

Nones, K. et al. (2014) Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International Journal of Cancer, 135(5), pp. 1110-1118. (doi: 10.1002/ijc.28765) (PMID:24500968)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi: 10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Quek, K. et al. (2014) A workflow to increase verification rate of chromosomal structural rearrangements using high-throughput next-generation sequencing. BioTechniques, 57(1), pp. 31-38. (doi: 10.2144/000114189)

Sjoquist, K. M. et al. (2014) Personalising pancreas cancer treatment: when tissue is the issue. World Journal of Gastroenterology, 20(24), pp. 7849-7863. (doi: 10.3748/wjg.v20.i24.7849) (PMID:24976722) (PMCID:PMC4069313)

Al-Ejeh, F. et al. (2014) Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(12), pp. 3187-3197. (doi: 10.1158/1078-0432.CCR-14-0048) (PMID:24838526)

Johns, A. L. et al. (2014) Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 6(5), 42. (doi: 10.1186/gm558) (PMID:24963353) (PMCID:PMC4067993)

Jamieson, N. B. , Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi: 10.1586/17474124.2014.893820) (PMID:24702631)

Weissmueller, S. et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell, 157(2), pp. 382-394. (doi: 10.1016/j.cell.2014.01.066) (PMID:24725405) (PMCID:PMC4001090)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi: 10.1016/j.gde.2013.12.001) (PMID:24480245)

Nagrial, A.M. et al. (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer, 110(2), pp. 313-319. (doi: 10.1038/bjc.2013.722) (PMID:24263063) (PMCID:PMC3899761)

Chang, D. K. , Grimmond, S. M., Evans, T. R.J. and Biankin, A. V. (2014) Mining the genomes of exceptional responders. Nature Reviews Cancer, 14(5), pp. 291-292. (doi: 10.1038/nrc3723) (PMID:25688402)

Chang, D. K. , Jamieson, N. B. , Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi: 10.1016/B978-0-12-386882-4.00034-7)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi: 10.1158/2159-8290.CD-14-0001)

Jamieson, N. B. , Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, C. J. and Vuong, Q. V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

2013

Kassahn, K. S. et al. (2013) Somatic point mutation calling in low cellularity tumors. PLoS ONE, 8(11), e74380. (doi: 10.1371/journal.pone.0074380) (PMID:24250782) (PMCID:PMC3826759)

Chang, D. K. , Jamieson, N. B. , Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi: 10.1200/JCO.2013.51.3176) (PMID:24043730)

Cowley, M.J., Chang, D.K. , Pajic, M., Johns, A.L., Waddell, N., Grimmond, S.M. and Biankin, A.V. (2013) Understanding pancreatic cancer genomes. Journal of Hepato-Biliary-Pancreatic Sciences, 20(6), pp. 549-556. (doi: 10.1007/s00534-013-0610-6) (PMID:23660961)

Cao, Y. et al. (2013) Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial 5 integrin. Cancer Research, 73(14), pp. 4579-4590. (doi: 10.1158/0008-5472.CAN-13-0529) (PMID:23689123) (PMCID:PMC3774599)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi: 10.1200/JCO.2012.46.8868) (PMID:23439753)

Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500(7463), pp. 415-421. (doi: 10.1038/nature12477)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi: 10.1186/gm482) (PMID:24004612) (PMCID:PMC3978667)

Liu, P.Y. et al. (2013) The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death and Differentiation, 20(3), pp. 503-514. (doi: 10.1038/cdd.2012.147) (PMID:23175188) (PMCID:PMC3569991)

2012

Biankin, A.V. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), pp. 399-405. (doi: 10.1038/nature11547) (PMID:23103869) (PMCID:PMC3530898)

Tactacan, C. M. et al. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 12(1), 395. (doi: 10.1186/1471-2407-12-395) (PMID:22958871) (PMCID:PMC3532183)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi: 10.1038/nature11114)

Humphris, J.L. et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology, 23(7), pp. 1713-1722. (doi: 10.1093/annonc/mdr561) (PMID:22241899) (PMCID:PMC3387824)

Mann, K. M. et al. (2012) Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(16), pp. 5934-5941. (doi: 10.1073/pnas.1202490109) (PMID:2242144) (PMCID:PMC1663246)

2011

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi: 10.1371/journal.pone.0029075) (PMID:22220202) (PMCID:PMC3248409)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2011) Molecular diagnostics in pancreatic cancer. In: Friess, H. and Hüser, N. (eds.) Advances in Pancreatic Cancer Treatment. Future Medicine Ltd., pp. 20-35. ISBN 9781780840703 (doi: 10.2217/EBO.11.330)

Scarlett, C. J. et al. (2011) Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS ONE, 6(10), e26088. (doi: 10.1371/journal.pone.0026088) (PMID:22022519) (PMCID:PMC3193536)

Pajic, M., Scarlett, C. J., Chang, D. K. , Sutherland, R. L. and Biankin, A. V. (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Human Genetics, 130(1), pp. 93-101. (doi: 10.1007/s00439-011-0990-0) (PMID:21516344)

Nguyen, N. Q. et al. (2011) Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. Journal of Gastroenterology and Hepatology, 26(2), pp. 267-274. (doi: 10.1111/j.1440-1746.2010.06466.x) (PMID:21261715)

Chong, J.J.H. et al. (2011) Adult cardiac-resident msc-like stem cells with a proepicardial origin. Cell Stem Cell, 9(6), pp. 527-540. (doi: 10.1016/j.stem.2011.10.002)

2010

Marshall, G.M. et al. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 29(44), pp. 5957-5968. (doi: 10.1038/onc.2010.332) (PMID:20697349)

2009

Leong, R. W.L., Chang, D. , Merrett, N. D. and Biankin, A. V. (2009) Taking optical biopsies with confocal endomicroscopy. Journal of Gastroenterology and Hepatology, 24(11), pp. 1701-1703. (doi: 10.1111/j.1440-1746.2009.06011.x) (PMID:20136953)

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi: 10.1200/JCO.2008.20.5104) (PMID:19398572)

Nguyen, N. Q., Biankin, A. V. , Leong, R. W. L., Chang, D. K. , Cosman, P. H., Delaney, P., Kench, J. G. and Merrett, N. D. (2009) Real time intraoperative confocal laser microscopy-guided surgery. Annals of Surgery, 249(5), pp. 735-737. (doi: 10.1097/SLA.0b013e3181a38f11) (PMID:19387332)

Gill, A. J. et al. (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 41(2), pp. 161-167. (doi: 10.1080/00313020802337329) (PMID:19320058)

Biankin, A.V. et al. (2009) Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology, 137(2), 558-568.e11. (doi: 10.1053/j.gastro.2009.04.009) (PMID:19376121)

Chang, D. K. , Nguyen, N. Q., Merrett, N. D., Dixson, H., Leong, R. W.L. and Biankin, A. V. (2009) Role of endoscopic ultrasound in pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 3(3), pp. 293-303. (doi: 10.1586/egh.09.18) (PMID:19485810)

2008

Colvin, E. K., Chang, D. K. , Merrett, N. D., Kench, J. G. and Biankin, A. V. (2008) Individualizing therapy for pancreatic cancer. Journal of Gastroenterology and Hepatology, 23(12), pp. 1779-1782. (doi: 10.1111/j.1440-1746.2008.05683.x) (PMID:19120869)

Das, A., Chang, D. , Biankin, A. V. and Merrett, N. D. (2008) Pancreatitis following human papillomavirus vaccination. Medical Journal of Australia, 189(3), p. 178. (doi: 10.5694/j.1326-5377.2008.tb01960.x) (PMID:18673112)

Chang, D. K. , Merrett, N. D. and Biankin, A. V. (2008) Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem? Journal of Gastroenterology and Hepatology, 23(7pt1), pp. 1036-1045. (doi: 10.1111/j.1440-1746.2008.05471.x) (PMID:18707598)

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi: 10.1038/sj.bjc.6604177)

Leong, R.W.L., Nguyen, N.Q., Meredith, C.G., Al–Sohaily, S., Kukic, D., Delaney, P.M., Murr, E.R., Yong, J., Merrett, N.D. and Biankin, A.V. (2008) In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology, 135(6), pp. 1870-1876. (doi: 10.1053/j.gastro.2008.08.054)

This list was generated on Fri Apr 19 00:19:13 2024 BST.

Jump to: Articles | Book Sections

Number of items: 145.

Articles

Horgan, D. et al. (2022) Meeting the need for a discussion of unmet medical need. Healthcare, 10(8), 1578. (doi: 10.3390/healthcare10081578) (PMID:36011235) (PMCID:PMC9408346)

Schwappacher, R. et al. (2021) Muscle-derived cytokines reduce growth, viability and migratory activity of pancreatic cancer cells. Cancers, 13(15), 3820. (doi: 10.3390/cancers13153820)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, 4330. (doi: 10.1038/s41467-020-17359-2) (PMID:32859912) (PMCID:PMC7455744)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

Grant, R. C. et al. (2018) Exome-wide association study of pancreatic cancer risk. Gastroenterology, 154(3), 719-722.e3. (doi: 10.1053/j.gastro.2017.10.015) (PMID:29074453) (PMCID:PMC5811358)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi: 10.1038/nature24026) (PMID:28953865)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi: 10.1038/nature21063) (PMID:28199314)

Biankin, A. V. (2017) The road to precision oncology. Nature Genetics, 49(3), pp. 320-321. (doi: 10.1038/ng.3796) (PMID:28232728)

Hardie, R.-A. et al. (2017) Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer and Metabolism, 5, 2. (doi: 10.1186/s40170-017-0164-1) (PMID:28163917) (PMCID:PMC5282905)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060) (PMID:27856273)

Kleeff, J. et al. (2016) Pancreatic cancer. Nature Reviews Disease Primers, 2, 16022. (doi: 10.1038/nrdp.2016.22) (PMID:27158978)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi: 10.1038/nature16965) (PMID:26909576)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi: 10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

McCarroll, J. A. et al. (2015) βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget, 6(4), pp. 2235-2249. (PMID:25544769) (PMCID:PMC4385848)

Humphris, J. L. et al. (2014) Clinical and pathologic features of familial pancreatic cancer. Cancer, 120(23), pp. 3669-3675. (doi: 10.1002/cncr.28863) (PMID:25313458)

Grimont, A. et al. (2014) SOX9 regulates ERBB signalling in pancreatic cancer development. Gut, 64(11), pp. 1790-1799. (doi: 10.1136/gutjnl-2014-307075) (PMID:25336113)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi: 10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Johns, A. L. et al. (2014) Returning individual research results for genome sequences of pancreatic cancer. Genome Medicine, 6(5), 42. (doi: 10.1186/gm558) (PMID:24963353) (PMCID:PMC4067993)

Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Pancreatic cancer genomics. Current Opinion in Genetics and Development, 24, pp. 74-81. (doi: 10.1016/j.gde.2013.12.001) (PMID:24480245)

Hidalgo, M. et al. (2014) Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discovery, 4(9), pp. 998-1013. (doi: 10.1158/2159-8290.CD-14-0001)

Kassahn, K. S. et al. (2013) Somatic point mutation calling in low cellularity tumors. PLoS ONE, 8(11), e74380. (doi: 10.1371/journal.pone.0074380) (PMID:24250782) (PMCID:PMC3826759)

Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500(7463), pp. 415-421. (doi: 10.1038/nature12477)

Chou, A. et al. (2013) Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 5(8), p. 78. (doi: 10.1186/gm482) (PMID:24004612) (PMCID:PMC3978667)

Liu, P.Y. et al. (2013) The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death and Differentiation, 20(3), pp. 503-514. (doi: 10.1038/cdd.2012.147) (PMID:23175188) (PMCID:PMC3569991)

Tactacan, C. M. et al. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 12(1), 395. (doi: 10.1186/1471-2407-12-395) (PMID:22958871) (PMCID:PMC3532183)

Pérez-Mancera, P.A. et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 486(7402), pp. 266-270. (doi: 10.1038/nature11114)

Colvin, E.K. et al. (2011) Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS ONE, 6(12), e29075. (doi: 10.1371/journal.pone.0029075) (PMID:22220202) (PMCID:PMC3248409)

Chong, J.J.H. et al. (2011) Adult cardiac-resident msc-like stem cells with a proepicardial origin. Cell Stem Cell, 9(6), pp. 527-540. (doi: 10.1016/j.stem.2011.10.002)

Chang, D.K. et al. (2009) Margin clearance and outcome in resected pancreatic cancer. Journal of Clinical Oncology, 27(17), pp. 2855-2862. (doi: 10.1200/JCO.2008.20.5104) (PMID:19398572)

Gill, A. J. et al. (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology, 41(2), pp. 161-167. (doi: 10.1080/00313020802337329) (PMID:19320058)

Murphy, N.C. et al. (2008) Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 98(3), pp. 537-541. (doi: 10.1038/sj.bjc.6604177)

Book Sections

This list was generated on Fri Apr 19 00:19:13 2024 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

Pancreatic Cancer AI for Genomics and Personalised Medicine (PANCAIM)
European Commission
2021 - 2025
PREDICT-Meso: PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma
Cancer Research UK
2020 - 2021
Precision-Panc: a dynamic therapeutic development platform for pancreatic cancer
Cancer Research UK
2019 - 2020
ECMC supplement
Chief Scientist Office
2019 - 2020
ICGC ARGO
Cancer Research UK
2019 - 2020
Health Data Research UK: Institute of Health and Biomedical Informatics
Health Data Research UK
2018 - 2023
ICGCmed involvement
Cancer Research UK
2017 - 2018
CRUK Centre Renewal
Cancer Research UK
2017 - 2019
Developing new clinically relevant positron emission tomography (PET) probes in Glasgow
Beatson Cancer Charity
2017 - 2022
Glasgow ECMC
Cancer Research UK
2017 - 2019
Glasgow ECMC
Chief Scientist Office
2017 - 2018
Precision Medicine Laboratory sequencing of patient tumour samples
Beatson Cancer Charity
2017 - 2022
Precision Panc
Cancer Research UK
2017 - 2019
University of Glasgow Human Cancer Models Initiative Pilot: Clinical Hub
Cancer Research UK
2016 - 2018
The Scottish Genomes Partnership
Chief Scientist Office
2016 - 2019
Using preoperative pancreatic endoscopic ultrasound to enable precision medicine for the management of pancreatic cancer
Pancreatic Cancer Research Fund
2015 - 2017
Glasgow Molecular Pathology (GMP) Node
Medical Research Council
2015 - 2019
Clinical Training Award Cycle 2
Cancer Research UK
2015 - 2018
Defining Platinum and PARP Responsive Molecular Phenotypes of Pancreatic Cancer.
Wellcome Trust
2015 - 2020
Italian pancreatic cancer genome initiative
ARC - NET Centre for Applied Research on Cancer
2015 - 2019
A Phase I study of Olaparib in Combination with Chemo-Radiation in Locally Advanced Pancreatic Cancer.
Cancer Research UK
2014 - 2020
CR-UK Centre renewal
Cancer Research UK
2014 - 2017
Genotype Guided Stratified Therapy for Pancreatic Cancer
Cancer Research UK
2014 - 2019

We use cookies

Necessary cookies

Analytics cookies

Hotjar and Clarity

Professor Andrew Biankin

Biography

Research interests

Publications

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

Articles

Book Sections

Grants